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Abstract : One of the reasons the health care system requires long-term nursing care 
for elderly patients is the risk of falls and fractures.  In this study, we sought to 
identify risk factors for drug-induced falls and fractures in elderly patients in Japan.  
Risk factors for drug-induced falls and fractures in the elderly were analyzed by 
searching for the Standardised Medical Dictionary for Regulatory Activities （Med-
DRA） query （SMQ） “accidents/injuries” in the Japanese Adverse Drug Event 
Report database （JADER）, as this SMQ was the most well suited for evaluating 
data on falls and fractures.  For elderly patients in Japan, the risk factors for drug-
induced accidents/injuries include age ≥ 70 years old, female sex, and treatment 
with specific drugs, but not polypharmacy.  Among the risk factors with the 10 
highest reporting odds ratios （RORs） were treatment with : anti-osteoporosis agents 
such as bisphosphonates （e.g., minodronic acid）, eldecalcitol and bazedoxifene ; 
dementia therapeutic agents such as rivastigmine and memantine ; antiparkinsonian 
agents such as entacapone and pramipexole ; and neuropathic pain relievers such as 
pregabalin.  Although various geriatric syndromes were generally caused by poly-
pharmacy, it has been posited that individual medications such as those mentioned 
above have a more signicant association with drug-induced accidents and injuries 
in the elderly than polypharmacy.  These drugs should be used cautiously while 
considering drug interruption, dose reductions, and switching to alternative therapies 
with lower risks.  An association between accidents/injuries and drugs targeting the 
central nervous system （such as hypnotics, sedatives, anxiolytics, and antidepres-
sants） has previously been reported.  However, in the present study, no elevated 
risks in association with triazolam, zopiclone, unitrazepam, diazepam, rilmazafone, 
estazolam, etizolam, or paroxetine were detected.  Using RORs for risk detection 
for drugs in the JADER database is accessible and useful, and enables sensitive 
risk detection.
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Introduction
　In Japan, life expectancy at birth for male and female individuals is 81.09 and 87.26 years, 
respectively, and has reached the highest level to date 1）.  The total population ≥ 75 years old is 
estimated to increase by 1.3 times from 16.32 million people （13.0％ aged ≥ 75 years） in 2015 
to 21.7 million people （18.1％ aged ≥ 75 years） in 2025 2）.  Healthy life expectancy （the average 
period of life during which health problems do not restrict daily life） in 2016 for males and 
females was 72.14 and 74.79 years, respectively 3）.  Smaller differences between life expectancy 
and healthy life expectancy would likely lead to healthier daily life in the population.  The top 
four reasons for requiring long-term nursing care among elderly users of long-term care insur-
ance in 2016 were dementia （18.0％）, cerebrovascular disease （stroke） （16.6％）, age-related frailty 
（13.3％）, and a fall or fracture （12.1％）4）.  Furthermore, fractures decrease quality of life 5）. 
Fracture prevention could therefore extend healthy life expectancy and curb rising medical costs.
　Drugs are known as one of the factors responsible for falls and fractures, and a guideline 
on appropriate use of drugs in the elderly was issued in May 2018 by the Ministry of Health, 
Labour and Welfare.  The guideline states that drug-induced geriatric syndromes are indicated 
by dizziness, falls, memory impairment, and delirium, and reports that high-risk drugs include 
antihypertensive agents, hypnotics, anxiolytics, antidepressants, antiepileptics, phenothiazines, antipar-
kinsonian agents, antihistamines, and memantine 6）.  
　Several studies on drug-induced falls and fractures in elderly patients, including studies on the 
use of multiple medications （polypharmacy）, have been conducted worldwide.  However, the 
results are not consistent ― they vary from study to study, and by country.  Moreover, in Japan, 
only sparse data have been collected at a nationwide level.
　The Pharmaceuticals and Medical Devices Agency （PMDA） controls the Japanese Adverse 
Drug Event Report database （JADER）, which includes spontaneous reports of adverse drug 
reactions （ADRs） from the pharmaceutical industry, medical institutions, and clinical trials since 
April 2004.  This database is accessible to the general public following agreement with the 
user policy.  Reports in JADER consist of the following four elds: “demographics （demoC-
CYYMM）,” “drug information （drugCCYYMM）,” “adverse event （reacCCYYMM）,” and 
“disease name （histCCYYMM）,” which are each associated with the same patient identication 
（ID） number 7）.  
　Several studies in the elderly have been conducted using JADER, such as analyses of high-risk 
drugs causing adverse events （AEs）, non-benzodiazepine-induced AEs, the prognosis of AEs, and 
the relationships between polypharmacy and factors such as multi-morbidity, renal function disor-
ders and liver function disorders 8，9）.  However, despite drug-induced falls and fractures being a 
considerable health-related issue for the elderly in Japan, no previous reports have analyzed the 
risk factors for such events using JADER.  One advantage of analyses performed using JADER 
is that the odds ratios （ORs） for specic drug/AE combinations can be calculated.  Another 
advantage is that relative risk level can be compared by OR to each specic drug and event 
of interest in the setting of Japan.  Thus, the purpose of this study was to explore relevant fac-
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tors and specic types of drugs that are associated with a high risk of a fall or fracture in the 
elderly using JADER.
Materials and methods
　Data in JADER that were collected from April 2004 to June 2017 were used.  Reported AEs 
are coded using the Preferred Term （PT） in the Medical Dictionary for Regulatory Activities 
（MedDRA）, developed by the International Council for Harmonisation of Technical Require-
ments for Pharmaceuticals for Human Use （ICH）, and stored in JADER 10）.  Notably, MedDRA 
is used by regulatory agencies and pharmaceutical industries worldwide.  However, directly and 
comprehensively searching for AEs in MedDRA is challenging because MedDRA consists of 
System Organ Classes （SOCs） with four sublevels of hierarchical organization, and PTs belong 
to different SOCs depending on the AE code.  Therefore, identical AEs may be grouped under 
different SOCs.  For example, a discrepancy could arise if the target AE is a “Renal disorder”, 
which belongs to the “Renal and urinary disorders” SOC, because “Blood urea nitrogen （BUN） 
increase” belongs to the “Investigations” SOC.  Even if AEs have the same meaning, they can 
be classied into different SOCs.  Standardised MedDRA Queries （SMQs） are tools developed 
to facilitate the retrieval of MedDRA-coded data and are used to support signal detection and 
monitoring.  SMQs comprise PTs in MedDRA related to specic medical conditions, and there 
are currently nearly one hundred SMQs.  The accidents and injuries SMQ （“accidents/injuries”） 
is dened as accidents and injuries associated with the use of medications, which include terms 
such as accidents, injuries, burns, trauma, falls, fractures, wounds, crush, and contusions 11）.  How-
ever, terms that refer to risk factors for accidents and injuries （e.g., sudden onset of sleep） are 
excluded 11）.  Also, accidents/injuries is a single term and cannot be separated.  Although acci-
dents/injuries covers a broader range of AEs than just falls and fractures, this SMQ was selected 
for our study because it provides sensitive signal detection for drug-induced falls and fractures, 
and such events can be individuated comprehensively.  
　Individual case reports and post-marketing surveillance by pharmaceutical companies are the 
main reported sources in JADER, so reported AEs are almost always caused by drugs.  There-
fore all AEs in the present study are referred to as ADRs.  
　Reported ADR events with a clear age range （including 0-9, 10-19, 20-29, 30-39, 40-49, 
50-59, 60-69, 70-79, 80-89, 90-99 and ≥ 100 years） were extracted from JADER.  ADRs were 
encoded by MedDRA/J Version 20.1, and ADRs matched to accidents/injuries were identied. 
Next, we checked whether ADRs corresponded to accidents/injuries in the database.  Miss-
ing sex data were treated as “unknown”.  Duplicate drugs （those with the same ID number） 
were excluded.  The numbers of drugs were counted and categorized as “1-5 drugs” and “ ≥ 6 
drugs.” The numbers of ADRs and numbers of ADRs corresponding to accidents/injuries were 
counted by age group and sex, and we determined whether the risks of ADRs corresponding to 
accidents/injuries differed according to sex and age.  The World Health Organization’s denition 
of elderly is ≥ 65 years old, but age groups are categorized in 10-year increments in JADER, so 
elderly patients in the present study were dened as those categorized as ≥ 70 years old.  Fac-
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tors relevant to ADRs which correspond to accidents/injuries for those aged 70 years or older 
were analyzed.  Drugs were categorized into small therapeutic categories, because there was a 
large number of drugs in the database 12）.  Signals relating to small therapeutic categories, and 
ADRs corresponding to accidents/injuries were examined.  Reports that included unknown drug 
names or over-the-counter medications were excluded from our analysis.  For signal detection, 
the reporting odds ratio （ROR） was used, and a 95％ condence interval （CI） was calculated. 
Each ROR was calculated using the following formula : 
　ROR＝（N11 / N21） / （N12 / N22）＝（N11 × N22） / （N12 × N21）
　Where, N11 and N12 are the numbers of certain and uncertain ADRs for the target drug, 
respectively, and N21 and N22 are the numbers of certain and uncertain ADRs for other drugs, 
respectively 13）.
　In the small therapeutic categories where signals were detected, the ROR was calculated for 
individual drugs.  The proportional relationship between the drug and detected accidents/injuries 
was calculated.  JMP Pro 14 （SAS Institute Inc., Cary, North Carolina, USA） was used for sta-
tistical analyses.  
Results
　A total of 749,054 ADR events （483,152 patients） were reported, including 696,794 events 
with a clear age range.  The population used for the risk factor analysis is shown in Fig. 1.  The 
number of ADRs and the number of ADRs corresponding to accidents/injuries categorized by 
age group and sex are shown in Fig. 2A and B, respectively.  The proportion of ADRs by age 
group was 24.4％, 23.1％, and 13.1％ in patients in their 70s, 60s, and 50s, respectively.  Further-
more, the proportion of ADRs corresponding to accidents/injuries was 28.2％, 23.7％, and 19.8％ 
in patients in their 70s, 80s, and 60s, respectively.  The average number of drugs used in indi-
vidual patients was 5.1-5.4 for patients aged 50-90 years （data not shown）.  In patients in their 
70s, the proportion of ADRs was 44.8％ and 54.6％ in female and male patients, respectively, 
whereas the proportion of ADRs corresponding to accidents/injuries was 63.9％ and 34.9％ in 
female and male patients, respectively, and there were more female than male patients listed in 
the database.  
　A multivariate analysis was performed using the total population, including the variables of 
sex, age group （＜ 70 years or ≥ 70 years）, and drug usage （≥ 6 or 1-5 drugs） （Table 1）.  The 
factors associated with ADRs corresponding to accidents/injuries were female sex （OR ［95％ 
CI］, 1.73 ［1.65-1.82］）, age ≥ 70 years （OR ［95％ CI］, 2.16 ［2.06-2.27］）, and 1-5 drugs used 
（OR ［95％ CI］, 1.52 ［1.44-1.60］）.
　Similarly, a multivariate analysis was performed using the elderly population （Table 2）.  The 
factors associated with ADRs corresponding to accidents/injuries were female sex （OR ［95％ 
CI］, 2.17 ［2.02-2.32］）, age 80-89 years （OR ［95％ CI］, 1.65 ［1.54-1.76］）, age 90-99 years （OR 
［95％ CI］, 1.73 ［1.51-1.98］） and 1-5 drugs used （OR ［95％ CI］, 1.60 ［1.49-1.71］）.  There was 
no relationship between multiple medications （polypharmacy） and accidents/injuries.
　Of the 171,218 patients with reported ADRs in the age group ≥ 70 years, 59 small therapeutic 
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categories such as drugs that were not used in patients who had experienced the ADRs cor-
responding to accidents/injuries （e.g., topical preparations, drugs used for diagnosis, and unknown 
drugs） were excluded.  Subsequently, the RORs for the remaining 164,730 patients were 
analyzed.  A total of 823,040 drugs were used to calculate the RORs.  The small therapeutic 
Fig. 1.   Flowchart showing the process of selecting patients for inclusion in the analyses 
of ADRs corresponding to the accidents/injuries SMQ.
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Age group < 10 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99 100＋
Female 41.6％ 62.7％ 60.6％ 58.4％ 52.5％ 47.9％ 44.7％ 44.8％ 52.4％ 67.1％ 68.1％
Male 52.9％ 36.1％ 38.8％ 41.0％ 47.1％ 51.6％ 54.7％ 54.6％ 46.4％ 31.0％ 27.6％
Total  4.4％  3.9％  3.7％  6.1％  7.9％ 13.1％ 23.1％ 24.4％ 11.9％  1.5％ 0.0％
Fig. 2.   Distribution of ADRs reported in patients by sex and age group （A）, and distribution of ADRs corresponding 
to accidents/injuries by sex and age group （B）. On each graph, the bars show numbers of patients by 
sex, and the lines show proportions of patients by sex and age group.  The table below each graph shows 
the proportions of female and male patients within each age group （excluding patients for whom sex was 
unknown）, and the proportions of total patients （female, male or unknown sex） within each age group.
Age group < 10 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99 100＋
Female 41.7％ 58.2％ 63.4％ 47.0％ 47.6％ 59.2％ 56.9％ 63.9％ 68.3％ 80.5％ 85.7％
Male 51.4％ 39.2％ 36.6％ 52.6％ 51.5％ 40.6％ 41.6％ 34.9％ 29.6％ 17.4％  0.0％
Total  1.1％  3.5％  1.4％  3.2％  5.4％ 10.0％ 19.8％ 28.2％ 23.7％  3.6％  0.1％
A
B
131Risk of Accidents and Injuries in Elderly Patients
categories with ROR values ＞ 1 and 95％ CIs that do not include 1, and the RORs for the 
individual drugs with many ADRs corresponding to accidents/injuries, are shown in Table 3. 
Higher ROR values were obtained for anti-osteoporosis drugs than for other agents, especially 
bisphosphonates, followed by anti-Alzheimer’s disease drugs and antiparkinsonian agents.  The 
10 highest ROR values included those for anti-osteoporosis agents such as bisphosphonates 
（minodronic acid ROR ［95％ CI］, 8.7 ［7.2-10.3］; eldecalcitol （ROR ［95％ CI］, 4.1 ［3.4-5.0］）; 
bazedoxifene ROR, ［95％ CI］, 4.5 ［3.0-6.7］）, dementia therapeutic agents such as rivastigmine 
（ROR ［95％ CI］, 5.5 ［4.3-7.1］） and memantine （ROR ［95％ CI］, 4.2 ［3.2-5.3］）, antiparkinso-
nian agents such as entacapone （ROR ［95％ CI］, 5.0 ［3.3-7.6］） and pramipexole （ROR ［95％ 
CI］, 4.0 ［2.9-5.5］）, and neuropathic pain relievers such as pregabalin （ROR ［95％ CI］, 3.5 ［3.1-
4.1］）.  Approximately 80％ of bisphosphonates were determined to be related to accidents/inju-
ries, whereas only 60-70％ and 20-30％ of anti-Alzheimer’s disease drugs and antiparkinsonian 
agents such as levodopa were associated with accidents/injuries.
　Individual drugs with ROR values ＞ 1 and 95％ CIs that do not include 1, other than anti-
osteoporosis agents, dementia therapeutic agents, antiparkinsonian agents and neuropathic pain 
relievers, were: limaprost （ROR ［95％ CI］, 2.0 ［1.6-2.5］）; antihyperphosphatemics such as 
Table 2.   Multivariate model estimates for risk of ADRs corresponding to 
accidents/injuries in the elderly population
Variable Odds ratio （95％ CI） P （based on χ2 test）
Sex
Male 1＊
< 0.0001
Female 2.17 （2.02-2.32）
Age group
70-79 1＊ NA
80-89 1.65 （1.54-1.76） < 0.0001
90-99 1.73 （1.51-1.98） < 0.0001
100＋ 2.46 （1.15-5.24） 　0.0197
Drug usage
≥ 6 1＊
< 0.0001
1-5 1.60 （1.49-1.71）
＊Reference category.
Table 1.   Multivariate model estimates for risk of ADRs corresponding to 
accidents/injuries in the total population
Variable Odds ratio （95％ CI） P （based on χ2 test）
Sex
Male 1＊
< 0.0001
Female 1.73 （1.65-1.82）
Age group
<   70 1＊
< 0.0001≥ 70 2.16 （2.06-2.27）
Drug usage
≥ 6 1＊
< 0.00011-5 1.52 （1.44-1.60）
＊Reference category.
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Table 3.  RORs for drugs with ADRs corresponding to accidents/injuries in the ROR analysis population
Drug names, organized by small therapeutic category
Numbers of ADRs corresponding to 
accidents/injuries
ROR 
（95％ CI）
Suspected 
drug＊
Specific drug Other drugs
TotalYes No Yes No
Other agents affecting metabolism （miscellaneous） 1,431 28,714 11,721 781,174 823,040 3.3 （3.1-3.5） NA
　Alendronate sodium 437 3,866 12,715 806,022 823,040 7.2 （6.5-7.9） 84.9％
　Sodium risedronate hydrate 231 2,260 12,921 807,628 823,040 6.4 （5.6-7.3） 84.8％
　Minodronic acid hydrate 139 999 13,013 808,889 823,040 8.7 （7.2-10.3） 84.2％
　Zoledronic acid 73 1,638 13,079 808,250 823,040 2.8 （2.2-3.5） 79.5％
　Denosumab 54 985 13,098 808,903 823,040 3.4 （2.6-4.5） 83.3％
　Raloxifene hydrochloride 32 1,066 13,120 808,822 823,040 1.9 （1.3-2.6） 34.4％
　Bazedoxifene acetate 26 356 13,126 809,532 823,040 4.5 （3.0-6.7） 76.9％
Agents affecting central nervous system （miscellaneous） 598 13,296 12,554 796,592 823,040 2.9 （2.6-3.1） NA
　Pregabalin 212 3,736 12,940 806,152 823,040 3.5 （3.1-4.1） 69.3％
　Donepezil hydrochloride 103 3,586 13,049 806,302 823,040 1.8 （1.5-2.2） 33.0％
　Rivastigmine 71 793 13,081 809,095 823,040 5.5 （4.3-7.1） 94.4％
　Memantine 67 998 13,085 808,890 823,040 4.2 （3.2-5.3） 67.2％
　Galantamine hydrobromide 44 752 13,108 809,136 823,040 3.6 （2.7-4.9） 72.7％
　Pramipexole hydrochloride 39 606 13,113 809,282 823,040 4.0 （2.9-5.5） 64.1％
Calcium preparations 64 1,501 13,088 808,387 823,040 2.6 （2.1-3.4） NA
　Calcium L-aspartate hydrate 41 866 13,111 809,022 823,040 2.9 （2.1-4.0） 13.3％
　Calcium lactate hydrate 15 414 13,137 809,474 823,040 2.2 （1.3-3.7） 19.5％
Vitamin A and D preparations 350 8,466 12,802 801,422 823,040 2.6 （2.3-2.9） NA
　Alfacalcidol 183 5,408 12,969 804,480 823,040 2.1 （1.8-2.4）  5.5％
　Eldecalcitol 118 1,780 13,034 808,108 823,040 4.1 （3.4-5.0） 30.0％
　Calcitriol 33 803 13,119 809,085 823,040 2.5 （1.8-3.6）  9.1％
Vitamins E preparations 13 339 13,218 865,595 823,040 2.4 （1.4-4.1） NA
　Tocopheryl acetate 13 339 13,139 809,559 823,040 2.4 （1.4-4.1）  0.0％
Antiparkinsonian agents 252 6,904 12,900 802,984 823,040 2.3 （2.0-2.6） NA
　Carbidopa hydrate - levodopa mixt 40 1,256 13,112 808,632 823,040 2.0 （1.4-2.7） 22.5％
　Levodopa - benserazide hydrochloride mixt 43 730 13,109 809,158 823,040 3.6 （2.7-5.0） 23.6％
　Amantadine hydrochloride 36 1,315 13,116 808,573 823,040 1.7 （1.2-2.4） 61.1％
　Entacapone 24 296 13,128 809,592 823,040 5.0 （3.3-7.6） 79.2％
　Selegiline hydrochloride 18 377 13,134 809,511 823,040 2.9 （1.8-4.7） 27.8％
　Vitamins K preparations 29 980 13,123 808,908 823,040 1.8 （1.3-2.6） NA
　Menatetrenone 28 968 13,124 808,920 823,040 1.8 （1.2-2.6）  3.6％
Cardiovascular agents （miscellaneous） 220 9,390 12,932 800,498 823,040 1.5 （1.3-1.7） NA
　Limaprost alfadex 76 2,354 13,152 807,534 823,040 2.0 （1.6-2.5）  5.3％
　Tocopherol nicotinate 21 1,246 13,131 808,642 823,040 1.0 （0.7-1.6）  0.0％
　Calcium polystyrene sulfonate 21 1,420 13,131 808,468 823,040 0.9 （0.6-1.4）  9.5％
　Lanthanum carbonate 17 349 13,135 809,539 823,040 3.0 （1.8-4.9） 29.4％
　Iron sucrose 14 480 13,138 809,408 823,040 1.8 （1.1-3.1）  0.0％
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Table 3.  RORs for drugs with ADRs corresponding to accidents/injuries in the ROR analysis population
Drug names, organized by small therapeutic category
Numbers of ADRs corresponding to 
accidents/injuries
ROR 
（95％ CI）
Suspected 
drug＊
Specific drug Other drugs
TotalYes No Yes No
Hypnotics, sedatives, and anxiolytics 460 20,221 12,692 789,667 823,040 1.4 （1.3-1.6） NA
　Zolpidem tartrate 131 4,397 13,021 805,491 823,040 1.8 （1.6-2.2） 37.4％
　Brotizolam 118 5,092 13,034 804,796 823,040 1.4 （1.2-1.7） 25.4％
　Triazolam 33 1,753 13,119 808,135 823,040 1.2 （0.8-1.6） 18.2％
　Alprazolam 29 1,036 13,124 808,852 823,040 1.7 （1.1-2.4） 28.6％
　Zopiclone 26 1,767 13,126 808,121 823,040 0.9 （0.6-1.3） 34.6％
　Flunitrazepam 23 1,449 13,129 808,439 823,040 1.0 （0.7-1.5） 26.1％
　Diazepam 20 1,076 13,132 808,812 823,040 1.1 （0.7-1.8）  5.0％
　Rilmazafone hydrochloride hydrate 8 652 13,144 809,236 823,040 0.8 （0.4-1.5） 12.5％
　Estazolam 12 561 13,140 809,327 823,040 1.3 （0.7-2.3）  8.3％
　Eszopiclone 15 314 13,137 809,574 823,040 2.9 （1.8-4.9） 46.7％
　Quazepam 8 156 13,144 809,732 823,040 3.2 （1.6-6.4） 75.0％
Psychotropics 516 23,232 12,636 786,656 823,040 1.4 （1.3-1.5） NA
　Etizolam 24 4,783 13,078 805,105 823,040 1.0 （0.8-1.2）  9.5％
　Quetiapine fumarate 40 1,231 13,112 808,657 823,040 2.0 （1.5-2.8） 62.5％
　Risperidone 38 1,340 13,114 808,548 823,040 1.8 （1.3-2.4） 50.0％
　Paroxetine Hydrochloride Hydrate 30 1,400 13,122 808,488 823,040 1.3 （0.9-1.9） 50.0％
　Carbamazepine 27 1,553 13,125 808,335 823,040 1.1 （0.7-1.6） 70.4％
Thyroid and parathyroid hormone preparations 87 4,060 13,065 805,828 823,040 1.3 （1.1-1.6） NA
　Teriparatide 32 536 13,105 806,794 823,040 3.7 （2.6-5.3） 59.4％
　Levothyroxine sodium 47 3,094 13,121 807,425 823,040 0.8 （0.5-1.1）  2.1％
　Methimazole 7 376 13,145 809,512 823,040 1.2 （0.5-2.4） 14.3％
　Propylthiouracil 1 54 13,151 809,834 823,040 1.1 （0.2-8.2）  0.0％
Antipyretics, analgesics, and anti-inammatory agents 665 32,157 12,487 777,731 823,040 1.3 （1.2-1.4） NA
　Tramadol hydrochloride 27 604 13,125 809,284 823,040 2.8 （1.9-4.1） 48.1％
　Neurotropin 45 1,098 13,107 808,790 823,040 2.5 （1.9-3.4）  2.2％
　Etodolac 45 1,601 13,107 808,287 823,040 1.7 （1.3-2.3）  6.7％
　Ketoprofen 48 1,908 13,104 807,980 823,040 1.6 （1.2-2.1）  2.1％
　Tramadol hydrochloride, acetaminophen 50 1,296 13,102 808,592 823,040 2.4 （1.8-3.2） 62.0％
　Acetaminophen 51 3,501 13,101 806,387 823,040 0.9 （0.7-1.2）  3.9％
　Diclofenac sodium 67 3,467 13,085 806,421 823,040 1.2 （0.9-1.5） 20.9％
　Celecoxib 85 3,830 13,067 806,058 823,040 1.4 （1.1-1.7） 18.8％
　Loxoprofen sodium hydrate 142 9,150 13,152 800,738 823,040 1.0 （0.8-1.1）  3.5％
Urogenital and anal organ agents （miscellaneous） 249 12,483 12,903 797,405 823,040 1.2 （1.1-1.4） NA
　Tamsulosin hydrochloride 51 3,269 13,101 806,619 823,040 1.0 （0.7-1.3） 17.6％
　Imidafenacin 14 447 13,138 809,441 823,040 1.9 （1.1-3.3） 14.3％
　Mirabegron 34 755 13,118 809,133 823,040 2.8 （2.0-3.9） 61.8％
　Propiverine hydrochloride 24 909 13,128 808,979 823,040 1.6 （1.1-2.4）  4.2％
　Solifenacin succinate 33 1,304 13,119 808,584 823,040 1.6 （1.1-2.2） 45.5％
NA：not applicable. ＊Proportion of ADRs corresponding to accidents/injuries judged to be due to the specic drug.
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lanthanum （ROR ［95％ CI］, 3.0 ［1.8-4.9］）; iron sucrose （ROR ［95％ CI］, 1.8 ［1.1-3.1］）; hyp-
notics, sedatives and anxiolytics such as the non-benzodiazepines zolpidem （ROR ［95％ CI］, 1.8 
［1.6-2.2］） and eszopiclone （ROR ［95％ CI］, 2.9 ［1.8-4.9］）, and the benzodiazepines brotizolam 
（ROR ［95％ CI］, 1.4 ［1.2-1.7］）, alprazolam （ROR ［95％ CI］, 1.7 ［1.1-2.4］） and quazepam 
（ROR ［95％ CI］, 3.2 ［1.6-6.4］）; antischizophrenia agents such as quetiapine （ROR ［95％ CI］, 
2.0 ［1.5-2.8］） and risperidone （ROR ［95％ CI］, 1.8 ［1.3-2.4］）; antipyretics ; and analgesics.  The 
list also included anti-inammatory agents such as tramadol （ROR ［95％ CI］, 2.8 ［1.9-4.1］）, 
neurotropin （ROR ［95％ CI］, 2.5 ［1.9-3.4］） and etodolac （ROR ［95％ CI］, 1.7 ［1.3-2.3］）, as 
well as overactive bladder agents such as mirabegron （ROR ［95％ CI］, 2.8 ［2.0-3.9］）.
Discussion
　The novel ndings reported in the present study reveal that the risk factors for drug-induced 
accidents and injuries were age ≥ 70 years old, female sex, and treatment with specic drugs 
rather than polypharmacy.  In addition, the study detected drugs associated with the risk of acci-
dents and injuries in Japan.  The number of ADRs corresponding to accidents/injuries was the 
largest in the 70-79-year-old group, and we posited that accidents/injuries would be one of the 
causes of health problems.  In female patients, the difference in the period between life expec-
tancy （87.26 years） and healthy life expectancy （74.79 years） is higher than that in male patients, 
and this difference is likely to contribute to accidents/injuries such as fractures.
　Several studies on drug-induced falls and fractures in elderly patients have been reported, 
including small, single-center studies conducted in Japan.  Although one group of Japanese 
researchers reported a risk of falls associated with hypnotic drugs, a second group reported a 
risk of falls associated with polypharmacy14，15）.  Moreover, there are limited nationwide data in 
Japan.  JADER is the only database that includes spontaneous reports of ADRs nationwide in 
Japan.  Therefore, the present study has provided robust information on risk factors for accidents 
and injuries in the elderly.
　In the present study, the risk of accidents/injuries was signicantly higher in patients using 1-5 
drugs than in the polypharmacy group （patients using ≥ 6 drugs）.  In terms of accidents and 
injuries, the risks posed by individual drugs should be considered rather than the number of 
drugs used by an individual.  Similar ndings have been reported by Lawlor et al, who found 
that chronic diseases and multiple co-morbidities are more critical predictors of falls than poly-
pharmacy in the elderly 16）.  Iihara et al have pointed out that medication class is a more crucial 
risk factor for fall-related fractures than a polypharmacy measure that does not take into account 
medication class 17）.
　In addition, the present study showed that the risk of drug-induced accidents/injuries is higher 
in females than males.  The number of patients with osteoporosis in Japan is estimated at 12.8 
million （3.0 million males, 9.8 million females）, and incidence of osteoporosis increases with 
age 18）.  Given the high RORs for osteoporotic drugs, the prevalence of osteoporosis may affect 
the risk of accidents/injuries in elderly females.  In addition, the reason for the high risk in ≥ 
70-year-old patients could be due to an increase in co-morbid Parkinson’s disease and dementia. 
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It is also possible that female sex, aging, and prevalence of co-morbidities such as osteoporosis, 
Parkinson’s disease and dementia are confounded.
　Drugs associated with the highest risk of accidents/injuries were those used to treat osteoporo-
sis, Alzheimer’s disease, and Parkinson’s disease.  Conversely, antischizophrenia agents, hypnotics, 
sedatives, and anxiolytics were not associated with high RORs.
　Interestingly, the bisphosphonates, which suppress fractures in patients with osteoporosis, had 
the highest RORs for accidents/injuries.  Although it might be posited that the increased fracture 
incidence could be due to the primary disease, the RORs of other osteoporotic drugs for acci-
dents/injuries are not as high as those for the bisphosphonates.  This could be because bisphos-
phonates are being used for patients with more severe osteoporosis.  However, since the risks 
of osteonecrosis of the jaw and atypical femur fractures increase with long-term bisphosphonate 
treatment 19，20）, an assessment of drug use （and the potential benet of a “drug holiday”） after 
treatment for a certain period has been proposed 21）.  Essentially, patients with osteoporosis are 
at high risk of fractures, so careful treatment is needed.
　Although pregabalin has been used as a neuropathic pain reliever, its associated ROR was 
high （3.5 ［95％ CI, 3.1-4.1］）.  The package insert for pregabalin includes a caution regarding 
the potential risk of fractures due to ADRs such as dizziness, somnolence, and loss of conscious-
ness, especially in the elderly 22）.  Therefore, drugs such as pregabalin should be carefully selected 
after weighing the risks and benets for individual patients.  
　A cost-effectiveness analysis of a home safety intervention aimed at preventing falls in 
impaired elderly people showed that this approach could reduce fall-related fractures in elderly 
females 23）.  This is because the incremental cost-effectiveness ratio of the home safety interven-
tion compared to no prevention was € 9,580 per quality-adjusted life years （QALY） in females 23）. 
This nding could apply to elderly Japanese females because the risk factors identied in our 
study included female sex and aging.
　Several studies have used JADER to evaluate the relationships between drugs and AEs. 
JADER contains causality data, such as the drug suspected to have caused the AE, concomitant 
drugs, and drug-drug interactions.  In some studies, only “suspected drug” data has been extract-
ed for analysis.  However, in the present study, drugs identied as contributing to a high risk 
of a fall or fracture were not always identied as the “suspected drug” in JADER.  Therefore, 
analyses that aim to detect the risk factors for AEs should not rely on suspected causality data.
　It has been reported that calculating the RORs from spontaneous report databases has advan-
tages over calculating proportional reporting ratios, and allows for estimation of relative risk 13）. 
Using RORs for risk detection for drugs in JADER is accessible and useful, and enables sensi-
tive risk detection.
　The association between accidents/injuries and drugs targeting the central nervous system, such 
as hypnotics, sedatives, anxiolytics, and antidepressants, has previously been reported 24-26）.  In 
contrast, in the present study, an elevated risk was not detected in association with triazolam, 
zopiclone, flunitrazepam, diazepam, rilmazafone, estazolam, etizolam, or paroxetine.  Since the 
information sources contained in JADER are spontaneous reports, pharmaceutical companies 
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mainly report individual cases to the PMDA, and many events might be serious ADRs as 
determined by physicians.  Indeed, there is a reporting bias as only some ADRs observed in 
clinical practice are reported, and the level of reporting can vary because of numerous factors 27）. 
Therefore, the present study may have underestimated risks, particularly those associated with 
hypnotics, sedatives, anxiolytics, and antidepressants.
　In conclusion, we identied the principal risk factors for drug-induced accidents and injuries 
in the elderly in Japan to be female sex and advanced age.  Specic medications have a more 
signicant association with drug-induced accidents and injuries in elderly than polypharmacy.  The 
top 10 ROR values included those for: anti-osteoporosis agents such as bisphosphonates （e.g., 
minodronic acid）, eldecalcitol and bazedoxifene ; dementia therapeutic agents such as rivastigmine 
and memantine ; antiparkinsonian agents such as entacapone and pramipexole ; and neuropathic 
pain relievers such as pregabalin.  These drugs should be used cautiously while considering drug 
cessation, dose reductions, and switching to similar therapeutic drugs with lower associated risks 
as alternative management strategies.
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